Robert Liptak - Globus Medical Independent Director
| GMED Stock | USD 51.27 0.02 0.04% |
Director
Mr. Robert W. Liptak serves as Independent Director of the Company. He was Managing Director of Clarus Ventures, LLC, a life sciences VC firm, since its inception in 2005. He has served as one of our directors since July 2007 and is a member of our Compensation Committee and our Audit Committee. He has over 20 years of experience in investment management focusing primarily on the establishment and management of various investment management businesses, including as a General Partner in MPM Capital, L.P., a healthcare VC firm, from 2001 to 2008. From 1995 to 2001, Mr. Liptak was a Partner with the Geometry Group, a diversified asset management firm focused on establishing investment management firms. From 1992 to 1995, Mr. Liptak was Vice President of Finance for Global Asset Management Inc., an asset management firm, and he began his career in 1986 with Price Waterhouse where he was a Manager in its Capital Markets Group. Mr. Liptak also serves on the board of directors of SFJ Cayman Corporationration, a privatelyheld company since 2007.
| Age | 53 |
| Tenure | 17 years |
| Professional Marks | MBA |
| Address | 2560 General Armistead Avenue, Audubon, PA, United States, 19403 |
| Phone | 610 930 1800 |
| Web | https://www.globusmedical.com |
Globus Medical Management Efficiency
The company has return on total asset (ROA) of 0.0477 % which means that it generated a profit of $0.0477 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0421 %, meaning that it created $0.0421 on every $100 dollars invested by stockholders. Globus Medical's management efficiency ratios could be used to measure how well Globus Medical manages its routine affairs as well as how well it operates its assets and liabilities. As of April 24, 2024, Return On Tangible Assets is expected to decline to 0.04. In addition to that, Return On Capital Employed is expected to decline to 0.03. At present, Globus Medical's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 82.5 M, whereas Return On Tangible Assets are forecasted to decline to 0.04.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Barbara Mowry | National Research Corp | 70 | |
| Adrian Dillon | HealthEquity | 63 | |
| Deborah Tate | HealthStream | 61 | |
| Dale Polley | HealthStream | 67 | |
| Brita Eilertsen | National Research Corp | 53 | |
| Thompson Dent | HealthStream | 68 | |
| Frank Corvino | HealthEquity | 68 | |
| JoAnn Martin | National Research Corp | 63 | |
| Frank Medici | HealthEquity | 53 | |
| Evelyn Dilsaver | HealthEquity | 62 | |
| Donald Berwick | National Research Corp | 71 | |
| Frank Gordon | HealthStream | 55 | |
| William Stead | HealthStream | 69 | |
| Harald Arnet | National Research Corp | N/A | |
| Gayle Wellborn | HealthEquity | 56 | |
| Martiny Harris | HealthStream | 59 | |
| Michael Shmerling | HealthStream | 62 | |
| Kjersti Kanne | National Research Corp | N/A | |
| Savita Acharya | National Research Corp | 41 | |
| Michael Leavitt | HealthEquity | 66 | |
| Jeffrey McLaren | HealthStream | 51 | |
Management Performance
| Return On Equity | 0.0421 | ||||
| Return On Asset | 0.0477 |
Globus Medical Leadership Team
Elected by the shareholders, the Globus Medical's board of directors comprises two types of representatives: Globus Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Globus. The board's role is to monitor Globus Medical's management team and ensure that shareholders' interests are well served. Globus Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Globus Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steve Zarrilli, Independent Director | ||
| David Paul, Co-Founder, Chairman, CEO, Chairman of Compensation Committee and Chairman of Nominating and Corporate Governance Committee | ||
| Eric Schwartz, Senior Vice President General Counsel | ||
| Mike Reeder, Ex Officer | ||
| Ann Rhoads, Independent Director | ||
| Robert Douglas, Independent Director | ||
| Andrew Murphy, Group President Commercial Operations | ||
| Steven Payne, VP Controller | ||
| Anthony Williams, Senior Vice President General Counsel | ||
| Kelly Esq, General VP | ||
| Kelly Huller, Senior Vice President General Counsel, Corporate Secretary | ||
| Stephen Zarrilli, Independent Director | ||
| Robert Liptak, Independent Director | ||
| James Tobin, Independent Director | ||
| Kurt Wheeler, Independent Director | ||
| Brian Kearns, Senior Relations | ||
| Brett Murphy, Group President of Commercial Operations | ||
| Richard Holifield, Ex Officer | ||
| Daniel Lemaitre, Independent Director | ||
| John Dowling, Ex Officer | ||
| Keith Pfeil, Chief Financial Officer, Senior Vice President | ||
| David Demski, Group President of Emerging Technologies, Director and Member of Nominating and Corporate Governance Committee | ||
| Daniel Scavilla, Executive Vice President, Chief Commercial Officer and President - Trauma | ||
| David Davidar, Co-Founder, Sr. VP of Operations and Director |
Globus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Globus Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0421 | ||||
| Return On Asset | 0.0477 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 6.94 B | ||||
| Shares Outstanding | 112.94 M | ||||
| Shares Owned By Insiders | 0.79 % | ||||
| Shares Owned By Institutions | 97.29 % | ||||
| Number Of Shares Shorted | 7.76 M | ||||
| Price To Earning | 73.16 X |
Globus Medical Investors Sentiment
The influence of Globus Medical's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Globus. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Globus Medical's public news can be used to forecast risks associated with an investment in Globus. The trend in average sentiment can be used to explain how an investor holding Globus can time the market purely based on public headlines and social activities around Globus Medical. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Globus Medical's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Globus Medical's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Globus Medical's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Globus Medical.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Globus Medical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Globus Medical's short interest history, or implied volatility extrapolated from Globus Medical options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Globus Medical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. For information on how to trade Globus Stock refer to our How to Trade Globus Stock guide.Note that the Globus Medical information on this page should be used as a complementary analysis to other Globus Medical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for Globus Stock analysis
When running Globus Medical's price analysis, check to measure Globus Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Globus Medical is operating at the current time. Most of Globus Medical's value examination focuses on studying past and present price action to predict the probability of Globus Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Globus Medical's price. Additionally, you may evaluate how the addition of Globus Medical to your portfolios can decrease your overall portfolio volatility.
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |
Is Globus Medical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Globus Medical. If investors know Globus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Globus Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.79) | Earnings Share 1.07 | Revenue Per Share 13.87 | Quarterly Revenue Growth 1.246 | Return On Assets 0.0477 |
The market value of Globus Medical is measured differently than its book value, which is the value of Globus that is recorded on the company's balance sheet. Investors also form their own opinion of Globus Medical's value that differs from its market value or its book value, called intrinsic value, which is Globus Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Globus Medical's market value can be influenced by many factors that don't directly affect Globus Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Globus Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Globus Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Globus Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.